SOPHiA GENETICS, a company involved in Data-Driven Medicine, has named the former Foundation Medicine CEO, Troy Cox, as its new chairman of the board of directors, effective 1 March 2020, it was reported on Thursday.

Cox is replacing Antoine Duchateau, who has served as chairman since 2013 and will continue as a board member. Cox joined the company in July of 2019 as a member of the board. Prior to FMI, he led US BioOncology for a period of growth as senior vice president and officer at Genentech, participating in the launch of nearly half of the products. Earlier, he held executive and senior positions at various healthcare companies including UCB BioPharmaceuticals, Sanofi-Aventis, and Schering-Plough.

Troy Cox, said, 'I'm proud to take a leadership role at this important time of expansion and to be part of SOPHiA GENETICS mission. Thanks to its global and universal approach that already benefits more than 1,000 hospital partners, SOPHiA is uniquely positioned to lead and promote an important movement in the entire ecosystem. Together, we democratise Data-Driven Medicine, enabling clinical experts to access the full potential of new-generation health data and positively impact patients' lives all around the world.'